Depreciation & Amortization 8,367(h)
Non-GAAP Measure Adjustments 3,364(i)
Pro Forma Adjusted EBITDA
(Non-GAAP Measure) $24,094
(a) Reflects deconsolidation of 750 Park Place and increased rent expense
paid to 750 Park Place, which is an affiliate that was not acquired in
(b) Reflects 1) excess salaries paid over senior management's pro forma
contractual levels and 2) an estimated increased $7.1 million of
additional annual amortization expense related to intangible assets
created by Chem Rx Corporation's acquisition of B.J.K. Inc.
(c) Reflects exclusion of interest income unrelated to B.J.K. Inc. prior
to the acquisition.
(d) Reflects estimated pro forma interest expense resulting from our new
capital structure after the close of the acquisition, using an assumed
3-month LIBOR rate of 5.00% and inclusive of deferred financing cost
(e) Reflects one-time payment of funds from a life insurance policy
following the death of an officer and stockholder of B.J.K. Inc.
(f) Reflects exclusion of the minority interest related to 750 Park Place.
750 Park Place is an affiliate that was not acquired in the
(g) Reflects adjustment for assumed corporate tax rate of 40%.
(h) Reflects depreciation & amortization of Chem Rx Corporation, excluding
contribution of 750 Park Place. 750 Park Place is an affiliate that
was not acquired in the transaction.
(i) Reflects 1) the exclusion of SG&A expenses unrelated to B.J.K. Inc.
prior to the acquisition and 2) certain professional fees and other
expenses not r
|SOURCE Chem Rx Corporation|
Copyright©2008 PR Newswire.
All rights reserved